Eurofins Scientific SE Stock Swiss Exchange
Stocks
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 13.02B 14.79B 12.34B 11.14B 20.99B 1,418B 21.26B 148B 56.8B 725B 55.52B 54.31B 2,324B | P/E 2026 * |
25x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 16.39B 18.61B 15.53B 14.02B 26.42B 1,784B 26.76B 186B 71.48B 912B 69.87B 68.35B 2,924B | EV / Sales 2026 * |
2.17x | EV / Sales 2027 * | 2.02x |
| Free-Float |
60.39% | Yield 2026 * |
1.07% | Yield 2027 * | 1.21% |
Last Transcript: Eurofins Scientific SE
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 14.79B | |
| +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | |
| -0.68% | +0.77% | +27.18% | +80.13% | 60.14B | |
| -2.40% | -1.44% | +5.09% | +33.60% | 48.15B | |
| -1.66% | -3.81% | +29.82% | +36.45% | 44.25B | |
| +2.16% | +5.06% | +357.85% | +702.33% | 43.99B | |
| -0.50% | +1.02% | +8.49% | +103.71% | 41.61B | |
| +3.32% | +3.49% | +11.18% | +51.23% | 29.97B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | |
| -2.55% | -8.69% | -24.64% | +337.49% | 24.93B | |
| Average | +0.71% | +1.97% | +55.68% | +162.43% | 44.09B | |
| Weighted average by Cap. | +0.85% | +1.83% | +59.91% | +153.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.53B 8.56B 7.14B 6.44B 12.15B 820B 12.3B 85.41B 32.87B 419B 32.13B 31.43B 1,345B | 7.94B 9.02B 7.52B 6.79B 12.8B 865B 12.97B 90.03B 34.65B 442B 33.87B 33.13B 1,417B |
| Net income | 531M 603M 503M 454M 856M 57.81B 867M 6.02B 2.32B 29.55B 2.26B 2.21B 94.75B | 660M 749M 625M 564M 1.06B 71.83B 1.08B 7.48B 2.88B 36.72B 2.81B 2.75B 118B |
| Net Debt | 3.37B 3.82B 3.19B 2.88B 5.43B 366B 5.5B 38.16B 14.68B 187B 14.35B 14.04B 601B | 3.03B 3.45B 2.87B 2.59B 4.89B 330B 4.95B 34.39B 13.23B 169B 12.94B 12.65B 541B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
